Decision: Favourable

Study Title:

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

  • NREC Code:

    23-NREC-CT-012

  • Decision:

    Favourable

  • Meeting Date:

    05/04/2023

  • Study Type:

    CT application

  • Principal Investigator:

    Dr Janusz Krawczyk

  • PI Institution:

    Galway University Hospital

  • Sponsor:

    European Myeloma Network (EMN)

Scroll to Top